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Abstract
Purpose Folate-based radiopharmaceuticals have the po-
tential to be used for imaging and therapy of tumours
positive for the folate receptor (FR). We describe the in
vitro and in vivo evaluation of a DOTA–folate conjugate.
Methods Radiolabelling of the DOTA-folate was carried
out via standard procedures using 111InCl3 and
177LuCl3,
respectively. The distribution coefficient (log D) was
determined in octanol/PBS (pH 7.4). Tissue distribution
was investigated in nude mice bearing KB tumour
xenografts at different time points after administration of
111In-DOTA-folate (radiofolate 1) or 177Lu-DOTA-folate
(radiofolate 2) (1 MBq, 1 nmol per mouse). Pemetrexed
(PMX, 400 μg) was injected 1 h prior to the radiofolate in
order to reduce renal uptake. Images were acquired with a
SPECT/CT camera 24 h after injection of the radiofolate
(40–50 MBq, 3 nmol per mouse).
Results The hydrophilic character of the DOTA-folate was
represented by a low log D value (radiofolate 1 −4.21±0.11).
In vivo, maximal tumour uptake was found 4 h after
injection (radiofolate 1 5.80±0.55% ID/g; radiofolate 2
7.51±1.25% ID/g). In FR-positive kidneys there was
considerable accumulation of the radiofolates (radiofolate
1 55.88±3.91% ID/g; radiofolate 2 57.22±11.05% ID/g;
4 h after injection). However, renal uptake was reduced by
preinjection of PMX (radiofolate 1 9.52±1.07% ID/g;
radiofolate 2 13.43±0.54% ID/g; 4 h after injection)
whereas the tumour uptake was retained (radiofolate 1
6.32±0.41% ID/g; radiofolate 2 8.99±0.43% ID/g; 4 h after
injection). SPECT/CT images clearly confirmed favourable
tissue distribution of the novel radiofolates and the positive
effect of PMX.
Conclusion The preliminary requirements for the therapeutic
use of the novel DOTA-folate are met by its favourable tissue
distribution that can be ascribed to its hydrophilic properties
and combined administration with PMX.
Keywords DOTA-folate . Pemetrexed . Folate receptor .
SPECT/CT. 177Lu
Introduction
The folate receptor (FR) is a promising target for imaging
and therapy of cancer and inflammatory diseases because of
its frequent overexpression in tumour cells (epithelial
cancers of the ovary, kidney, colon, lung etc. [1–4]) and
activated macrophages [5], but limited expression in normal
tissues and organs, and also because of its high affinity for
folic acid (KD <10
−9 M) even in its conjugated state that
allows the use of this vitamin as a molecular “Trojan
Horse” to carry conjugated probes into FR-positive patho-
logical cells.
Folate-based conjugates of several radionuclides (99mTc
[6–11], 111In [7, 12], 66/67/68Ga [13, 14] and 18F [15]) for
SPECT and PET imaging purposes have been developed
and successfully evaluated in preclinical and clinical studies
[16, 17]. For therapeutic purposes, the FR has been
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exploited using folic acid conjugates with a variety of
cargoes such as chemotherapeutics [18], liposomes with
entrapped drugs [19], oligonucleotides and genes [20], and
haptens for FR-targeted immunotherapy [21, 22]. In
particular the number of folic acid-targeted small molecular
weight chemotherapeutics has increased rapidly. Administra-
tion of folate conjugates of mitomycin C [23], maytansinoid
[24] and vinca alkaloids [25, 26] has been shown to result in
effective tumour cell regression in preclinical studies in vitro
and in tumour (xeno)grafted mice. These promising results
led to the investigation of folic acid-targeted chemother-
apeutics in phase 1 and 2 clinical trials.
Folate-based radiotherapy, however, has not been envis-
aged until now because significant and FR-specific uptake
of radiofolates in the kidneys [8, 10, 11, 27] involves the
risk of radionephrotoxicity. Small molecular weight folate
radiopharmaceuticals encounter the same fate as folates that
are filtered in the glomeruli and reabsorbed from primary
urine via FRs located in the proximal tubule cells of the
renal tissue [28–32]. In a clinical trial with 111In-DTPA-
folate a similar tissue distribution of radioactivity was
detected in patients as previously found in mice including a
significant radiofolate uptake in the kidneys [12]. Thus, the
mouse serves as a useful animal model for predicting the
tissue distribution of folate-based radiopharmaceuticals in
humans. In a comparative study, Parker et al. investigated
the FR expression levels in organs and tissues of different
species [4]. They demonstrated that the density of FRs in
human kidneys most closely resembles that in mice.
During our research developing and evaluating radio-
folates, we have discovered that undesired kidney uptake is
significantly reduced when the antifolate pemetrexed
(PMX, Alimta) is injected shortly before the radiofolate
[33, 34]. PMX is a multitargeted antifolate that has
demonstrated promising clinical activity in a wide variety
of solid tumours, in particular in mesothelioma and non-
small-cell lung cancer, but also in cancer of the bladder,
cervix, colorectum, head and neck etc. [35, 36]. The
“antifolate effect” was discovered using our organometallic
99mTc/188Re-radiofolate tracers [33, 37, 38] and was
corroborated with other radiofolates, such as the clinically
tested 111In-DTPA-folate [12]. Based on these results, we
proposed a general validity of the effect of PMX on renal
uptake of radiofolates independent of the radiofolate ligand,
the chelating system and the radiometal, respectively.
Although we hypothesize that, due to their structural
similarities, radiofolates and PMX interact and compete for
FR binding in the proximal tubule cells of the kidneys, the
exact mechanism of our observation has not been elucidated
yet and is still the subject of current investigations.
The folate conjugate used in this study comprised a
DOTA chelator suitable for coordination with a variety of
diagnostic radionuclides (e.g. 111In, 67/68Ga, 64Cu) and
therapeutic radionuclides (e.g. 177Lu, 67Cu, 90Y). We
describe here the evaluation of DOTA-folate radiolabelled
with 111In and 177Lu. 111In is a diagnostic radionuclide with
γ energies (171 keV, 245 keV) ideal for SPECT imaging
purposes and thus is frequently used in diagnostic nuclear
medicine. 177Lu is a radiolanthanide that emits β radiation
(490 keV) with a tissue penetration range appropriate for
treatment of small tumours and metastases. The low β
energy together with its long half-life (6.7 days) make it a
promising isotope for radiopharmaceutical treatment of
solid tumours as demonstrated in a number of clinical
applications [39–41]. In addition, 177Lu emits γ radiation
(113 keV, 210 keV) detectable by SPECT, allowing
physicians to use it for monitoring therapy.
The aim of this study was to test and evaluate the novel
DOTA-folate in vitro and in vivo. The use of an established FR-
positive KB tumour xenografted mouse model allowed com-
parison with previously developed radiofolates. Biodistribution
studies and imaging studies were performed with 111In- and
177Lu-radiolabelled DOTA-folate (radiofolates 1 and 2, respec-
tively) alone and in combination with PMX for selective
reduction of radiofolate uptake in the kidneys. The results were
compared with those of our previously evaluated radiofolates
and discussed in relation to their potential use for therapeutic
purposes.
Materials and methods
Synthesis of the DOTA-folate conjugate
The DOTA-folate ligand (Fig. 1) was prepared by the Cu
(I)-catalysed [3+2] cycloaddition of azides and terminal
alkynes, a transformation which has been denoted as a
“click reaction” [42, 43]. The use of click chemistry for
Fig. 1 Chemical structure of the
DOTA-folate ligand
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conjugation of the DOTA-chelator to other biomolecules
has been reported [44, 45]. In brief, Cu(I)-catalysed
reaction of folic acid-γ-(4-azido)-butaneamide [46] with
an alkyne derivatized DOTA-chelator yielded under opti-
mized reaction conditions the DOTA-folate ligand in good
yield (45% yield for three steps; purity >98%) after
purification by HPLC (high-resolution MS data: m/z
([M+Na]+ calculated for C42H58N16O12Na: 1001.4318,
found 1001.4308). Details of the synthetic procedures will
be described elsewhere.
Radiolabelling
A stock solution (10 μl) of the DOTA-folate ligand (10−3 M)
was added to 250 μl sodium acetate buffer, 0.4 M, pH 5.
Then, radioactivity (111InCl3, Mallinckrodt-Tyco, Petten,
The Netherlands, or 177LuCl3, Nuclear Research and
Consultancy Group, NRG, Petten, The Netherlands) was
added (10–370 MBq) and the reaction solution was heated
for 30 min at 90°C. DTPA (10 μl, 10−3 M) was added for
complexation of potential traces of unreacted 111In or 177Lu.
Quality control was performed by HPLC which revealed a
radiochemical purity of >90%. The HPLC system com-
prised a Waters system with a tunable absorbance detector
and a Unispec multichannel analyser γ-detector and a
Waters Symmetry C-18 reversed-phase column (5 mm,
25 cm×4.6 mm) with an eluent that consisted of aqueous
0.05 M triethylammonium phosphate buffer, pH 2.25, and
methanol with a linear gradient to 80% methanol over
30 min. The highest specific activity (37 MBq/nmol) tested
resulted in a radiochemical purity of 92%. For the
biodistribution studies the radiolabelling was performed at
low specific activity (1MBq/nmol) allowing a radiochemical
purity of 98%. The remaining amount of radioactivity
(<10%) was determined to be free 111In and 177Lu
complexed by the DTPA that had been added. For in vitro
cell experiments radiofolate 1 was separated from unla-
belled DOTA-folate by HPLC diluted in phosphate buffered
saline (PBS) to a radioactivity concentration of 1.7 MBq/ml
(PBS; pH 7.4). For in vivo studies radiotracers 1 and 2 were
used without separation from unlabelled DOTA-folate.
Radiofolates 1 and 2 were diluted with NaCl 0.9% to the
desired specific activity (1 MBq, 1 nmol per mouse for
biodistribution studies; 40–50 MBq, 3 nmol per mouse for
SPECT imaging) for immediate administration to the mice.
Determination of the octanol/PBS distribution coefficient
(log D)
For comparison of the hydrophilic/lipophilic character, the
distribution coefficient (log D) of radiofolate 1 was
determined by a procedure published in the literature [47].
In brief, a sample of HPLC-purified radiofolate 1 (150 kBq)
was mixed with equal amounts (1.5 ml) of PBS (pH 7.4) and
octanol. The resulting biphasic system was mixed vigorously
for 1 min and the two phases were separated by centrifugation
for 5 min. Aliquots of 0.5 ml were taken from each layer and
counted for radioactivity in a γ-counter. The distribution
coefficient was expressed as the ratio of counts per minute
measured in the octanol phase to the counts per minute
measured in the PBS phase. The results represent the mean
(±SD) of six measurements for each compound.
Cell culture
KB cells (human nasopharyngeal carcinoma cell line; CCL-17)
were purchased from American Type Culture Collection
(ATCC,Manassas, VA). The cells were cultured as monolayers
at 37°C in a humidified atmosphere containing 5% CO2.
Importantly, the cells were cultured in a folate-free cell culture
medium, FFRPMI (modified RPMI, without folic acid,
vitamin B12 and phenol red; Cell Culture Technologies,
Gravesano/Lugano, Switzerland). FFRPMI medium was
supplemented with 10% heat-inactivated fetal calf serum
(FCS, as the only source of folate), L-glutamine and anti-
biotics (penicillin/streptomycin/fungizone). Routine culture
treatment was performed twice a week with EDTA
(2.5 mmol/l) in PBS.
In vitro cell studies
KB cells were seeded in 12-well plates (7.5×105 cells/well)
18 h prior to the experiment to form confluent monolayers
overnight. For all of the in vitro studies we used radiofolate
1. All experiments were performed in triplicate.
Time-dependent uptake of 111In-DOTA-folate Cell mono-
layers were rinsed with PBS (pH 7.4). Pure FFRPMI
medium (without FCS/L-glutamine/antibiotics, 975 μl) was
added into each well. Blocking studies were performed
with FFRPMI medium (475 μl) and a folic acid solution
(200 μM, 500 μl). The well plates were preincubated at 37°C
for 45 min. A solution of the radiofolate tracer (25 μl,
1.5 MBq/ml) was added to each well and the well plates were
incubated for 0, 5, 15, 30, 60, 120 and 240 min at 37°C. The
supernatants were removed and the monolayers washed several
times. Radioactivity counted in samples washed with only PBS
could be ascribed to the sum of FR-bound radiotracer on the
cell surface plus the internalized fraction. Cell samples washed
with stripping buffer (an aqueous solution of 0.1 M acetic acid
and 0.15 M NaCl, pH 3) in order to release radiotracers from
FRs on the cell surface enabled determination of the
internalized fraction of radioactivity [48, 49].
Uptake of 111In-DOTA-folate in combination with PMX The
experiment was performed as described above. PMX was
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added in different concentrations (0–10 μM) and the well
plates were incubated at 37°C for 45 min. After addition of
the radiofolate, the well plates were incubated at 37°C for
another 2 h. Then, each well was washed tree times with
ice-cold PBS, pH 7.4. The monolayers were lysed in 1 N
NaOH (1 ml), transferred to 4-ml tubes, and homogenized
by vortexing. The radioactivity of each sample was
measured with a γ-counter (Wizard, 1480, Perkin Elmer).
The concentration of proteins was determined for each
sample in order to normalize measured radioactivity of the
samples with respect to the averaged sample protein content
that accounted for 0.5 mg protein per well. The raw data
were converted from counts per minute into percentage of
total radioactivity added to each well.
Biodistribution studies
All animal experiments were approved by the governing
Animal Welfare Committee and conducted in accordance
with the regulations of the Erasmus Medical Center,
Rotterdam, The Netherlands. Female athymic nude mice
(NMRI nu/nu) at 6–8 weeks of age were purchased from
Charles River Laboratories (Maastricht, The Netherlands).
The animals were fed with a folate-deficient rodent diet
starting 5 days prior to tumour cell inoculation [50]. Mice
were inoculated with KB cells (5×106 cells in 100 μl PBS)
into the subcutis of each shoulder. Animal experiments
were performed approximately 14 days after tumour cell
inoculation, when the tumour had reached a size of
approximately 0.5–1.5 cm3.
Biodistribution studies were performed in triplicate.
Radiofolates 1 and 2 were administered to the mice in a
volume of 100 μl via a lateral tail vein. PMX (Alimta,
LY231514; Eli Lilly, Bad Homburg, Germany) was diluted
with NaCl 0.9% according to the instructions of the
manufacturer and injected into a lateral tail vein (400 μg
in 100 μl), 1 h prior to the radiotracer. Blocking studies
were performed with excess folic acid dissolved in PBS
(100 μg/100 μl) and intravenously injected immediately
before the radiotracer. The animals were killed at 1 h, 4 h,
24 h or 48 h after administration of radiofolate 1 or 2 alone
or with either preinjected PMX or coinjected folic acid.
Selected tissues and organs were collected, weighed, and
counted for radioactivity in a γ-counter (Wizard, 1480,
Perkin Elmer). The results were recorded as percentage of
the injected dose per gram of tissue (% ID/g), using
reference counts from a definite sample of the original
injectate that was counted at the same time. Statistical
analyses were performed using a t-test (Microsoft Excel
software). All analyses were two-tailed and considered as
type 3 (two sample unequal variance). A p-value of <0.05
was considered statistically significant.
SPECT/CT imaging
SPECT scans were performed with a four-headed multi-
plexing multipinhole camera (NanoSPECT/CT; Bioscan,
Washington DC) [51]. Each head was equipped with
tungsten-based collimator of nine 1.4-mm diameter pin-
holes, imaging a cylindrical field of view 37 mm in
diameter and 16 mm in length. The axial field of view
was extended using a step-and-shoot helical (SPECT) or
continuous (CT) acquisition mode with the user defining a
range of 16–230 mm according to the region to be imaged.
The acquisitions in mice bearing subcutaneous KB tumours
were performed 24 h after injection of radiofolate 1 and 2. The
time per view was chosen as 120–150 s, resulting in a total
scan duration of approximately 60 min. CT scans were
performed with an integrated CT scanner using a tube voltage
of 45 kV and an exposure time of 1500 ms per view. After
acquisition, SPECT data were reconstructed iteratively with
HiSPECT software (Scivis). The CT reconstruction used
cone-beam filtered back-projection. SPECTand CT data were
automatically coregistered as both modalities shared the same
axis of rotation. The fused datasets were analysed with
InVivoScope (Bioscan) postprocessing software.
Results
Determination of log D values
The octanol/PBS (pH 7.4) distribution coefficients (log D
values) were determined with radiofolate 1 and two
organometallic 99mTc radiofolates that had been evaluated
previously in our laboratories (Table 1). For the novel
radiofolate 1 we determined a log D value of −4.21±0.11, a
value significantly lower than that determined for the 99mTc
radiofolates. These results indicate the desired increase in
hydrophilicity of radiofolate 1 compared to the organome-
tallic 99mTc radiofolates.
In vitro cell experiment
In vitro cell binding experiments were performed with
DOTA-folate radiolabelled with 111In. FR-specific binding
of the radiofolate was proved by an experiment with excess
Table 1 Octanol/PBS (pH 7.4) distribution coefficients (log D values)
Folate radiotracer Log D
111In-DOTA-folate −4.21±0.11
99mTc(CO)3-His-folate −3.47±0.05
99mTc(CO)3-PAMA-folate −2.12±0.01
The values are the averages ±SD of six experiments.
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cold folic acid that resulted in an almost complete blockade
of radiofolate uptake (<0.5% cell binding of total added
radioactivity). The time-dependent experiment showed a
constantly increasing cellular uptake of radiofolate 1 until
steady state was reached after 2 h at 37°C. The internalized
fraction of radiofolate 1 accounted for 25–30% of total cell
uptake (sum of FR-bound radiofolate on the cell surface
and internalized fraction). The time course of the cellular
uptake of radiofolate 1 was largely comparable to the
results found with organometallic 99mTc radiofolates as
previously reported by our group [10].
Cell experiments in combination with PMX showed that
PMX does not influence radiofolate 1 uptake over a
concentration range up to 1 μM. Only a PMX concentration
of 10 μM led to a marked reduction in radiofolate uptake to
approximately 50% of controls (Fig. 2).
Biodistribution studies
Biodistribution studies of radiofolates 1 and 2 were carried
out under conditions important for potential therapeutic use.
In vivo evaluation was performed in athymic nude mice
bearing KB tumour xenografts, the standard animal model
for FR-targeting studies.
The results of the tissue distribution of radiofolates 1 and
2 are presented in Tables 2 and 3. The tumour uptake was
highest 4 h after injection (radiofolate 1 5.80±0.55% ID/g;
radiofolate 2 7.51±1.25% ID/g) and almost completely
retained over the time of investigation. The radiofolates
were quickly cleared from the blood stream and only
negligible amounts of radioactivity were found in the lungs,
spleen, stomach, muscle and bones. However, in the liver a
relatively high accumulation of radioactivity was observed
at early time points (radiofolate 1 5.20±2.00% ID/g;
radiofolate 2 4.63±1.12% ID/g; 4 h after injection), that
decreased over time. In the kidneys, very high accumulation
of radioactivity (about 57% ID/g, 4 h after injection) was
found for both radiofolates 1 and 2. It is noteworthy that the
tumour-to-kidney ratios were very low at all time points
investigated (radiofolate 1 <0.12; radiofolate 2 <0.16).
Besides the kidneys and tumours, FR-specific accumulation
was found in the salivary glands. The highest uptake in the
salivary glands was found shortly after injection of the
radiofolates, but radioactivity accumulation decreased over
the time of investigation. Importantly, preinjection of the
antifolate PMX led to a significant improvement in the
overall tissue distribution of the radiofolates. In FR-positive
kidneys a significant reduction in radioactivity uptake
(p<0.05) was found after injection of PMX. Also in the
salivary glands uptake was slightly reduced in mice that
received PMX. Tumour uptake, on the other hand, was not
impaired by PMX (radiofolate 1 6.32±0.41% ID/g; radio-
folate 2 8.99±0.43% ID/g, 4 h after injection). Thus, after
injection of PMX, the tumour-to-kidney ratio was increased
sevenfold for radiofolate 1 and fivefold for radiofolate 2.
SPECT/CT imaging
Imaging experiments were performed with a high-resolution/
high-sensitivity small-animal SPECT/CTcamera. Mice were
injected with radiofolate 1 or 2 (40–50MBq) with or without
preinjection of PMX. Whereas 99mTc radiofolates and
111In-radiofolates have been successfully used for SPECT
imaging studies in our previous work [34, 52], this was
the first time that SPECT/CT had been performed with a
177Lu-radiolabelled folate conjugate.
Figure 3 shows a SPECT/CT scan of a mouse 24 h after
injection of radiofolate 2 as a control and a mouse that had
been injected with PMX 1 h before radioactivity adminis-
tration. Both mice showed radioactivity accumulation in
FR-positive KB-tumour xenografts located on each shoulder.
Whereas radioactivity accumulation in the renal tissue of the
control mouse was very high (Fig. 3a), a considerable
reduction in radioactivity uptake was seen in the kidneys of
the mouse that received PMX (Fig. 3b). The same experiment
performed with radiofolate 1 showed similar results (data not
shown). It has to be mentioned that the higher amount of
DOTA-folate (3 nmol per mouse) used for SPECT/CT scans
compared to the amount used for biodistribution studies
(1 nmol per mouse) resulted in a slightly reduced radiofolate
uptake in normal tissues and organs (e.g. salivary glands).
Discussion
In our previous work we have developed organometallic
radiofolates for potential use in diagnostic (99mTc, γ-
Fig. 2 Uptake of radiofolate 1 in KB tumour cells pre-/coincubated
with different concentrations of PMX. The cell uptake was calculated
per 0.5 mg protein and is indicated as percentage of total added
radioactivity. *Nonspecific binding after addition of excess folic acid
(<0.5%); **significantly reduced cell uptake with 10 μM PMX
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radiation) and therapeutic (188Re, β-radiation) nuclear
medicine. The evaluation of these radiofolates in tumour-
bearing mice revealed specific accumulation in FR-positive
tumours and kidneys. However, we found unfavourably
high background radiation in the abdomen as a result of the
hepatobiliary excretion of these compounds, presumably
due to the lipophilic tricarbonyl core. High background
radiation would prevent the detection of small lesions in the
abdomen and even more problematic, a high activity dose
burden caused by therapeutic radiation would damage
healthy organs and tissues. Therefore, it is generally
desirable to develop hydrophilic radiopharmaceuticals that
are largely excreted via the kidneys. Kidneys are radiation-
sensitive organs, but there are effective methods routinely
used in the clinic for kidney protection such as, for
example, infusion of amino acids [53, 54].
In the case of folate-based radiopharmaceuticals, high
kidney uptake is a consequence of specific binding to FRs
Table 3 Biodistribution of radiofolate 2 in KB tumour-bearing female nude mice expressed as % ID/g.
Tissue Time after radiofolate 2 injection
1 h 4 h 24 h 48 h With preinjected PMXa
1 h 4 h 24 h 48 h
Blood 0.12±0.02 0.06±0.03 0.03±0.01 0.02±0.01 0.17±0.06 0.03±0.00 0.03±0.02 0.02±0.00
Lung 0.91±0.01 0.75±0.10 0.53±0.14 0.43±0.13 0.81±0.10 0.49±0.06 0.39±0.11 0.31±0.06
Spleen 0.30±0.04 0.28±0.05 0.20±0.02 0.11±0.01 0.30±0.08 0.16±0.01 0.14±0.02 0.11±0.01
Kidneys 47.06±3.17 57.22±11.05 45.10±1.21 42.68±4.96 16.13±4.42 13.43±0.54 11.87±1.67 9.58±1.48
Stomach 1.81±0.13 1.92±0.60 1.26±0.06 0.78±0.11 1.52±0.31 1.42±0.10 0.96±0.10 0.66±0.14
Intestines 0.52±0.07 0.43±0.20 0.27±0.06 0.24±0.10 0.49±0.16 0.54±0.04 0.24±0.04 0.17±0.04
Liver 4.81±0.52 4.63±1.12 2.13±0.24 1.60±0.44 5.12±2.41 1.87±0.01 1.26±0.23 0.96±0.10
Salivary glands 5.38±0.42 5.02±1.07 3.41±0.31 2.50±0.12 5.21±0.72 4.01±0.22 2.14±0.35 1.54±0.20
Muscle 0.88±0.12 0.70±0.05 0.55±0.12 0.33±0.10 0.66±0.09 0.57±0.05 0.37±0.05 0.28±0.02
Bone 0.56±0.05 0.46±0.03 0.35±0.09 0.21±0.08 0.49±0.07 0.30±0.06 0.22±0.05 0.21±0.03
Tumour 7.37±0.94 7.51±1.25 6.78±1.87 4.99±0.98 8.71±0.36 8.99±0.43 8.61±1.36 5.04±0.73
Tumour-to-blood 63.14±4.20 125.07±34.59 272.13±128.58 277.17±183.62 51.19±29.04 268.61±7.33 397.99±202.16 266.15±31.21
Tumour-to-liver 1.54±0.23 1.61±0.36 3.29±1.25 3.29±0.98 1.60±1.25 4.80±0.21 7.17±2.34 5.29±1.02
Tumour-to-kidney 0.16±0.03 0.13±0.02 0.15±0.04 0.12±0.02 0.51±0.32 0.67±0.01 0.72±0.05 0.54±0.14
a 400 μg, injected 1 h before the radiotracer.
Table 2 Biodistribution of radiofolate 1 in KB tumour-bearing female nude mice expressed as % ID/g.
Tissue Time after radiofolate 1 injection
1 h 4 h 24 h 4 ha With preinjected PMXa
1 h 4 h 24 h
Blood 0.20±0.09 0.08±0.02 0.06±0.02 0.02±0.00 0.19±0.06 0.07±0.01 0.04±0.01
Lung 0.86±0.14 0.70±0.06 0.62±0.03 0.05±0.00 0.76±0.05 0.62±0.22 0.42±0.01
Spleen 0.31±0.05 0.30±0.09 0.16±0.04 0.06±0.01 0.22±0.07 0.19±0.01 0.18±0.02
Kidneys 46.34±5.18 55.88±3.91 43.55±6.69 3.53±1.18 10.52±2.46 9.52±1.07 8.56±1.00
Stomach 1.85±0.36 1.70±0.31 1.55±0.35 0.04±0.00 1.39±0.34 1.49±0.25 1.24±0.28
Intestines 0.55±0.05 0.43±0.06 0.35±0.03 0.09±0.00 0.50±0.11 0.63±0.38 0.48±0.32
Liver 6.95±2.67 5.20±2.00 2.23±0.64 0.26±0.06 3.90±0.48 1.96±0.44 1.10±0.26
Salivary glands 5.29±0.48 6. 13±1.84 3.17±0.98 0.10±0.03 3.75±0.66 3.54±0.37 2.33±0.20
Muscle 0.78±0.10 0.61±0.10 0.60±0.08 0.01±0.00 0.55±0.10 0.67±0.14 0.40±0.06
Bone 0.60±0.09 0.53±0.03 0.40±0.09 0.03±0.01 0.36±0.10 0.49±0.17 0.40±0.05
Tumour 4.41±1.22 5.80±0.55 4.85±0.95 0.31±0.01 6.11±1.11 6.32±0.41 6.28±0.93
Tumour-to-blood 23.62±4.10 71.81±20.83 92.96±28.93 32.59±7.06 93.52±16.79 142.52±9.93
Tumour-to-liver 0.65±0.12 1.33±0.61 2.23±0.41 0.60±0.15 3.34±0.74 5.99±1.95
Tumour-to-kidney 0.09±0.02 0.10±0.01 0.11±0.02 0.57±0.27 0.67±0.09 0.75±0.18
a 100 μg folic acid, injected 5 min before the radiotracer.
b 400 μg, injected 1 h before the radiotracer.
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that are substantially expressed in the proximal tubule cells.
A potential application of folate-based radionuclide therapy
requires (1) a hydrophilic radiofolate compound that is
cleared via kidneys, but at the same time (2) a method to
inhibit selectively radiofolate uptake via FRs in the kidneys
without affecting FR-mediated uptake in the tumour. In this
study we demonstrated that both requirements can be
addressed successfully by using hydrophilic folic acid
radiotracers in combination with PMX.
The novel folate conjugate features a DOTA-chelator
which is a polar macrocycle that allows easy radiolabelling
with a variety of diagnostic (e.g. 111In, 67/68Ga, 64Cu) and
therapeutic radionuclides (e.g. 177Lu, 90Y, 67Cu). The
distribution coefficient (log D) of the 111In-radiolabelled
DOTA-folate determined in octanol and PBS (pH 7.4) was
favourably decreased compared to that of organometallic
99mTc radiofolates. Finally, we successfully applied the
method of preinjecting PMX previously established in our
laboratory in order to reduce undesired renal retention of
the novel radiofolate [33].
The in vivo evaluation was performed with radiofolates 1
and 2. It is noteworthy that biodistribution studies were
performed with an amount of folate ligand that would allow
the administration of a therapeutic amount of 177Lu which is
usually around 37 MBq per mouse. This aspect was not
considered in our previous studies with organometallic
99mTc/188Re radiofolates [10, 11, 37]. However, experiments
in our own laboratories (unpublished data) and those in
others have shown that the mass of the injected compound
(e.g. folate-based or peptide-based radiopharmaceuticals) can
critically affect its tissue distribution [55]. In particular in
receptor-positive normal tissues and organs radioactivity
accumulation is often dependent on the amount of injected
targeting compound. Therefore, it is crucial to perform the
evaluation studies of a therapeutically useful radiofolate
under the conditions that would be applied for therapy
experiments. It has to be critically acknowledged that the
amount of DOTA-folate injected for the SPECT/CT imaging
studies was not the same as for the biodistribution studies. A
slightly lower uptake of radiofolate in normal organs (e.g. in
salivary glands) in mice used for SPECT/CT scans than in
mice used in biodistribution studies might have been a
consequence thereof.
Not surprisingly, both radiofolate 1 and radiofolate 2
showed superior tissue distribution than our organometallic
99mTc radiofolates [10, 11, 52]. The hydrophilic character
of the DOTA-folate ligand prevented undesired excretion
via the intestinal tract and therefore almost no background
activity was found in the abdomen. Overall, the tissue
distribution profiles of radiofolates 1 and 2 were largely
comparable to that of the clinically tested 111In-DTPA-
folate [34]. As expected, radioactivity uptake (% ID/g) in
the kidney was much higher than the uptake in the tumour
xenografts. This situation is disadvantageous for a potential
therapeutic application. However, we were able to show
that preadministration of PMX resulted in a significant
reduction in renal radioactivity accumulation that improved
tumour-to-kidney ratios significantly. In vitro, we were able
to demonstrate that concentrations up to 1 μM PMX did not
affect the uptake of radiofolate 1 into cancer cells indicating
that PMX and radiofolates do not compete for the same
binding sites in tumour cells. On the other hand, it remains
unclear whether the reduction in radiofolate uptake in the
kidneys after PMX injection was based on a blockade of the
FRs by PMX or whether another, pharmacological effect
was responsible for inhibition of the radiofolate uptake.
Based on the results of this study, we conclude that our
DOTA-folate fulfils the preconditions for a potential
therapeutic agent when combined with PMX. However,
one has to critically acknowledge that PMX is a chemo-
therapeutic drug with anticancer activity and thus potential
undesired side effects. This might be a problematic issue
when PMX is solely used for kidney protection. However,
it is likely that the combination of radiofolate 2 with PMX
would result in an additive or synergistic effect to induce
tumour regression. Corresponding experiments are currently
ongoing in our laboratories.
Fig. 3 Three-dimensional SPECT/CT images of KB tumour-bearing
mice 24 h after injection of radiofolate 2: (a) control mouse and (b)
mouse injected with PMX 1 h prior to the radiofolate
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